Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
Provided By GlobeNewswire
Last update: May 15, 2025
- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagene
zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult
and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) -
